-+ 0.00%
-+ 0.00%
-+ 0.00%

Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

Benzinga·05/28/2026 17:18:42
Listen to the news
Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.